|Bid||0.00 x 3000|
|Ask||0.00 x 800|
|Day's Range||4.65 - 4.94|
|52 Week Range||3.43 - 19.50|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.00|
Yahoo Finance's Seana Smith and Jared Blikre discuss all the afternoon trading action.
On Wednesday, June 06, 2018, US markets saw broad based gains with eight out of nine sectors finishing the trading sessions in green. All you have to do is sign up today for this free limited time offer by clicking the link below.
SELLAS Life Sciences Group, Inc. (SLS) (“SELLAS” or “the Company”) today announces interim Phase 1 data of GPS in combination with nivolumab in patients with WT1+ ovarian cancer in second or third remission after salvage chemotherapy at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation, “A phase I study of concomitant galinpepimut-S (GPS) in combination with nivolumab (nivo) in patients (pts) with WT1+ ovarian cancer (OC) in second or third remission,” is being delivered by Roisin E. O’Cearbhaill, M.D., Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, during the “Gynecologic Cancer” session from 1:15 to 4:45 p.m. CT.
SELLAS Life Sciences Group Inc., (SLS) (SELLAS) today announced that the sponsor-principal investigator, after taking into account that key clinical development objectives were met as well as other regulatory considerations, and in agreement with SELLAS, determined to terminate early the Phase 2b independent investigator-sponsored clinical trial (IST) of trastuzumab (Herceptin®) +/- nelipepimut-S (NeuVax™) in HER2 1+/2+ breast cancer patients. In this Phase 2b study, Herceptin® was provided under a Clinical Trial Supply Agreement by Genentech, Inc. The decision to early terminate this Phase 2b study was based in part on the previously announced recommendation of the independent Data Safety Monitoring Board (DSMB) to further advance the development of the NeuVax + Herceptin combination for the triple negative breast cancer (TNBC) patient population.
NEW YORK, May 17, 2018-- SELLAS Life Sciences Group Inc., today announced that data from the Company’ s ongoing Phase 1/ 2 study of galinpepimut-S in combination with Bristol Myers Squibb’ s nivolumab ...
SELLAS Life Sciences Group Inc. (SLS) (“SELLAS”), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range of cancer indications, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its novel drug candidate, galinpepimut-S (GPS), for the treatment of multiple myeloma (MM).
SELLAS Life Sciences Group, Inc. (SLS) (“SELLAS” or “the Company”), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range of cancer indications, today announced the closing of the second tranche of its $10,700,000 private placement transaction. In March 2018, SELLAS entered into a definitive securities purchase agreement to issue shares of its convertible preferred stock and warrants to purchase shares of its common stock in a private placement transaction to a select group of institutional investors, in the United States and Europe.
NEW YORK, April 20, 2018-- SELLAS Life Sciences Group Inc.,, a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range of cancer indications, today announced ...
NEW YORK, April 16, 2018-- SELLAS Life Sciences Group Inc., a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range of cancer indications, today reported financial ...
Sellas Life Sciences Group Inc (NASDAQ: SLS ) popped as much as 189 percent Monday after reporting “clinically meaningful activity” in interim data for its Phase 2b NeuVax trial. H.C. Wainwright liked ...
Clinically meaningful activity in favor of investigational nelipepimut-S+ Herceptin arm. Clinically and statistically significant efficacy in triple negative breast cancer cohort; p= 0.023. NEW YORK, April ...
SELLAS Life Sciences Group Inc’s (NASDAQ:SLS): SELLAS Life Sciences Group, Inc., a development-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications. With the latestRead More...
SELLAS Life Sciences Group Inc (NASDAQ:SLS), a $39.50M small-cap, operates in the healthcare industry, which faces key trends such as rising demand fuelled by an aging population and the growingRead More...
Today, I will be analyzing SELLAS Life Sciences Group Inc’s (NASDAQ:SLS) recent ownership structure, an important but not-so-popular subject among individual investors. The impact of a company’s ownership structure affectsRead More...